





RESEARCH ARTICLE

SNPs in *IL4* and *IFNG* show no protective associations with human African trypanosomiasis in the Democratic Republic of the Congo: a case-control study [version 1; peer review: 2 approved]

Olivier Fataki Asina^{1,2}, Harry Noyes³, Bruno Bucheton⁴, Hamidou Ilboudo ^{5,6}, Annette MacLeod⁷, Dieudonné Mumba Ngoyi ^{1,8}, TrypanoGEN Group, as members of The H3Africa Consortium

¹National Institute of Biomedical Research (INRB), Kinshasa, Democratic Republic of the Congo

²School of Medicine, University of Uele, Isiro, Democratic Republic of the Congo

³Center for Genomic Research, University of Liverpool, Liverpool, L69 7ZB, UK

⁴IRD-CIRAD 177, Montpellier, 34398, France

⁵Centre International de Recherche-Développement sur l'Élevage en zones Subhumides (CIRDES), Bobo-Dioulasso, Burkina Faso

⁶Institut de Recherche en Sciences de la santé (IRSS)-Unité de Recherche Clinique de Nanoro (URCN), Nanoro, Burkina Faso

⁷Wellcome Centre for Molecular Parasitology, University of Glasgow, Glasgow, G12 8TA, UK

⁸School of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo

V1 First published: 04 Aug 2020, 3:35
<https://doi.org/10.12688/aasopenres.12999.1>

Latest published: 04 Aug 2020, 3:35
<https://doi.org/10.12688/aasopenres.12999.1>

Abstract

Background: Human African trypanosomiasis (HAT) is a protozoal disease transmitted by tsetse flies. Infection with trypanosomes can lead directly to active HAT or latent infection with no detectable parasites, which may progress to active HAT or to spontaneous self-cure. Genetic variation could explain these differences in the outcome of infection. To test this hypothesis, polymorphisms in 17 candidate genes were tested (*APOL1* [*G1* and *G2*], *CFH*, *HLA-A*, *HPR*, *HP*, *IL1B*, *IL12B*, *IL12RB1*, *IL10*, *IL4R*, *MIF*, *TNFA*, *IL6*, *IL4*, *IL8*, *IFNG*, and *HLA-G*).

Methods: Samples were collected in Democratic Republic of the Congo. 233 samples were genotyped: 100 active HAT cases, 33 from subjects with latent infections and 100 negative controls. Commercial service providers genotyped polymorphisms at 96 single nucleotide polymorphisms (SNPs) on 17 genes. Data were analyzed using Plink V1.9 software and R. Loci, with suggestive associations (uncorrected $p < 0.05$) validated using an additional 594 individuals, including 164 cases and 430 controls.

Results: After quality control, 87 SNPs remained in the analysis. Two SNPs in *IL4* and two in *IFNG* were suggestively associated (uncorrected $p < 0.05$) with a differential risk of developing a *Trypanosoma brucei gambiense* infection in the Congolese population. The *IFNG* minor allele (rs2430561, rs2069718) SNPs were protective in comparison

Open Peer Review

Reviewer Status  

Invited Reviewers

1

2

version 1

04 Aug 2020




report



report

1. **Emile Chimusa** , University of Cape Town, Cape Town, South Africa

2. **Charles D. Kato** , Makerere University, Kampala, Uganda

Any reports and responses or comments on the article can be found at the end of the article.

between latent infections and controls. Carriers of the rs2243258_T and rs2243279_A alleles of *IL4* and the rs2069728_T allele of *IFNG* had a reduced risk of developing illness or latent infection, respectively. None of these associations were significant after Bonferroni correction for multiple testing. A validation study using more samples was run to determine if the absence of significant association was due to lack of power.

Conclusions: This study showed no evidence of an association of HAT with *IL4* and *IFNG* SNPs or with *APOL1 G1* and *G2* alleles, which have been found to be protective in other studies.

Keywords

Human African Trypanosomiasis, T.b.gambiense, genes, polymorphisms



This article is included in the African Society of Human Genetics gateway.

Corresponding author: Dieudonné Mumba Ngoyi (mumbadieudonne@yahoo.fr)

Author roles: **Fataki Asina O:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Resources, Software, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Noyes H:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Bucheton B:** Conceptualization, Formal Analysis, Funding Acquisition, Methodology, Validation, Visualization, Writing – Review & Editing; **Ilboudo H:** Conceptualization, Data Curation, Formal Analysis, Methodology, Validation, Visualization, Writing – Review & Editing; **MacLeod A:** Conceptualization, Formal Analysis, Funding Acquisition, Methodology, Project Administration, Supervision, Validation, Visualization, Writing – Review & Editing; **Mumba Ngoyi D:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Validation, Visualization, Writing – Review & Editing;

Competing interests: No competing interests were disclosed.

Grant information: This study was funded by the Wellcome Trust under the Human Health and Heredity in Africa Consortium (H3Africa) initiative [099310/Z/12/Z]. TrypanoGEN is an initiative of the H3Africa programme of the African Academy of Science (AAS). *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2020 Fataki Asina O *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Fataki Asina O, Noyes H, Bucheton B *et al.* **SNPs in *IL4* and *IFNG* show no protective associations with human African trypanosomiasis in the Democratic Republic of the Congo: a case-control study [version 1; peer review: 2 approved]** AAS Open Research 2020, 3:35 <https://doi.org/10.12688/aasopenres.12999.1>

First published: 04 Aug 2020, 3:35 <https://doi.org/10.12688/aasopenres.12999.1>

Introduction

Human African trypanosomiasis (HAT), or sleeping sickness, is a neglected tropical disease caused by infection with extracellular blood protozoan parasites, which are transmitted by the bite of the tsetse fly (*Glossina sp*) (Headrick, 2014).

The disease is present in more than 250 foci in Africa and nearly 70 million people are at risk of infection with the two human-infective forms. A chronic form is found in Central and Western Africa and is caused by *Trypanosoma brucei gambiense* (*Tbg*); an acute form is caused by *Trypanosoma brucei rhodesiense* (*Tbr*) and is found in East Africa. About 97% of all HAT cases are due to *Tbg* infection, which causes a chronic disease with a long latency period (Kennedy, 2013).

There is currently no vaccine against HAT. The control of *Tbg* HAT is mainly based on the active detection of infected cases followed by their treatment and also vector control. After infection, the parasites may be undetectable by microscopy for months or years; these cases are known as latent infections and are detected by serology. Active HAT with microscopically detectable parasites evolves in two successive stages: stage 1 (haemolympathic) and stage 2 (meningoencephalitis, also known as neurological). The transition from stage 1 to stage 2 is a consequence of the parasites crossing the blood-brain barrier. For a long time, HAT was considered fatal if untreated; however, the dogma that HAT is 100% fatal has been questioned (Jamonneau *et al.*, 2012). It is now recognised that some individuals self-cure after developing a latent infection.

The Democratic Republic of the Congo (DRC) is the country with the highest incidence of HAT. More than half of districts are endemic for HAT, with more than 36 million people at risk (Report of a WHO Expert Committee, 2013). There was an increase in the number of new cases at the end of the 20th century in both rural and urban areas; however, the number of cases is currently decreasing, with fewer than 3,000 cases detected in 2015 (Büscher *et al.*, 2017).

There are several HAT foci in DRC with very different clinical presentations and outcomes, which could be explained by the presence of genetically different subpopulations of humans and possibly parasites, as well as environmental factors (Kande Betu Kumesu, 2012). There is also variation in disease phenotype within populations, which may be partly due to individual genetic variation.

Several genes have been implicated in the control of other infectious diseases (AIDS, tuberculosis, malaria, etc.), but genetic data on HAT are more recent and incomplete. For example, differences in cytokine levels and other immunological markers may be a consequence of differences in disease states or of genetic differences between individuals in these cytokine genes or in genes that regulate them.

Polymorphisms in *IL6*, *IL10*, *IL1A* and *TNFA* have been associated with risk of developing HAT (Bucheton *et al.*, 2011; Courtin *et al.*, 2006; Courtin *et al.*, 2007) in the DRC, although only

the association with *IL6* remained significant after Bonferroni correction. An *HLA-G* haplotype has also been associated with HAT susceptibility in a Congolese population (Courtin *et al.*, 2013).

It has also been reported that levels of interleukins *IL8* and *IL10* increase during infection and then decrease after treatment (Lejon *et al.*, 2002) and that the stages of the disease are also correlated with levels of *IL6* and *IL10* (Ilboudo *et al.*, 2012; Sternberg *et al.*, 2005). Our study is designed to investigate polymorphisms in candidate genes that have previously been implicated in the outcome of HAT, in an active focus in DRC.

Methods

Ethical statement

The study protocol was submitted to the ethics committee of the National Ministry of Public Health (DRC) and approved under number 1/2013 and by the Ethics Advisory Committee (EACC) of the Institute for Research and Development (IRD), Marseille.

All enrolled subjects signed an informed consent form written in French which was translated into the local language if necessary. Parents or guardians signed consent forms on behalf of minors when they couldn't sign themselves and they had given verbal consent.

Study design

This study was one of six studies of populations of HAT endemic areas in Guinea, Cameroon, Ivory Coast, DRC, Malawi and Uganda (Ahouty *et al.*, 2017; Kabore *et al.*, 2017; Kamoto *et al.*, 2019; Kimuda *et al.*, 2018; Ofon *et al.*, 2017). The studies were designed to have 80% power to detect odds ratios (OR) >2 for loci with disease allele frequencies of 0.15 – 0.65, with the 96 single nucleotide polymorphisms (SNPs) genotyped for 100 cases and 100 controls.

Study site

Our study was conducted in the district of Masi-Manimba, in the province of Kwilu, which was formerly a part of Bandundu province, in the south-west of the DRC, more than 388 km from Kinshasa.

Recruitment

The study was undertaken in two stages: 1) a screen of 96 candidate loci in 233 subjects and 2) a validation study of two loci that were suggestively positive in the first round in 594 additional subjects.

Subjects were aged at least 12 years old and were enrolled in this study from July 2013 to March 2016 during the active screening campaigns of the mobile team of the National Program of Control of Human African Trypanosomiasis (PNLTHA). Participants were recruited in their respective villages during active screening campaigns. Simultaneous serological (Card Agglutination Test for Trypanosomiasis; CATT) testing and parasitological examination were performed. Samples that were CATT positive and lymph node fluid or Buffy coat positive for trypanosomes by microscopy were subject to the immune

trypanolysis test, which is highly specific for *T. b. gambiense* (Van Meirvenne *et al.*, 1995).

The immune trypanolysis test allows to confirm or not the presence of *T. b. gambiense* specific antibodies in an individual. Individual's plasma was collected in a 2 ml cryotube in the field, kept in a cryocontainer filled with liquid nitrogen and brought to the laboratory where plasma was stored in deep freezer -80°C. Live particular strains of *T. b. gambiense*, LiTat 1.3 and LiTat 1.5, were incubated with plasma as well as with guinea pig serum, serving as a source of complement. If the *T. b. gambiense* specific antibodies are present in the plasma, they bind to trypanosomes that will be lysed. Absence of trypanosome mobility, observed under a microscope, implied a positive result.

Cases (stages 1 and 2) were recruited from the positive test subjects for CATT, for whom parasitological evaluation confirmed the presence of the parasites in blood or lymph node fluid (for stage 1) and/or cerebrospinal fluid (CSF) (for stage 2).

Controls were CATT negative individuals living in the same area as cases and for whom the trypanolysis test was negative.

The subjects with latent infections were individuals who were negative by microscopy despite positive CATT and positive trypanolysis test results.

Controls and subjects with latent infections were enrolled as a comparison group. The first have never been in contact with *T.b.gambiense*, the latter have been in contact with *T.b.gambiense* but in this group, the parasite is no longer found in the absence of any treatment.

Individuals who could not provide a sufficient volume of blood (less than 9 ml) or were under 12 years old were excluded. Previously treated patients were not included as controls.

Sample collection and processing

At inclusion, blood was collected through venepuncture by a skilled technician of PNLTHA using two heparin tubes of 5 ml. The first tube was used for serological (CATT) and parasitological examinations (capillary tube centrifugation [CTC], or mini-Anion Exchange Column Trypanosoma on Buffy Coat [mAECT-BC]). The second tube was used to collect plasma and buffy coat in 2 ml cryotubes. These two last samples were taken after centrifugation at 3500 rpm of the blood in the heparinized tube for 5 minutes. In addition, if the individual had shown enlargement of cervical ganglia, they were punctured and lymph node fluid examined by direct examination for trypanosomes. Once the trypanosome was isolated either in lymph node fluid or in the blood, the cerebrospinal fluid (CSF) was collected by lumbar puncture and examined for stage determination of the disease according to PNLTHA instructions. Plasma and Buffy coat were kept in containers filled with liquid nitrogen until they were sent to INRB where plasma was stored in the freezer at -20 ° C and Buffy coat in liquid nitrogen for subsequent DNA extraction for genotyping. DNA was extracted from Buffy Coat using the Maxwell16 Promega kit following

the manufacturer's instructions (Maxwell®16 Tissue DNA Purification kit, cat# AS1030), quantified by Nanodrop (Thermo Scientific Nanodrop 2000, ISOGEN, Life Science) and then stored at -20°C. All DNA were sent to Makerere University, Uganda where they were quantified by Qubit®3.0 Fluorometer (Invitrogen by Life Technologies) prior to shipment for genotyping. DNAs were shipped at room temperature. Transportation lasted less than 48 hours.

Genotyping

Samples were submitted to Plateforme Genome Transcriptome de Bordeaux at INRA Site de Pierroton. A multiplex assay (two sets of 40 SNPs) was designed using Assay Design Suite v2.0 (Agena Biosciences). SNP genotyping was achieved with the MassArrayiPLEX genotyping assay using the iPLEX Gold genotyping kit (Agena Biosciences, cat# 10148-2) described in Gabriel *et al.* (2009). Products were detected on a MassArray mass spectrophotometer and data were acquired in real time with MassArray RT software 4.0.0.2 (Agena Biosciences). SNP clustering and validation was carried out with Typer 4.0.26.75 software (Agena Biosciences). All monomorphic SNPs and loci displaying more than three clusters of genotypes or unclear cluster delimitation were filtered out. 11 SNP that failed genotyping on the MassArray platform and 16 additional SNPs were genotyped by LGC Genomics, Hoddesden, UK (rs1143629, rs3212227, rs2546890, rs1130363, rs1233330, rs1818879, rs1801275, rs1424241, rs8062041, rs7185840, rs152828, rs375947, rs11575934, rs11548056., rs136174, rs73885316, rs136177, rs143830837, rs71785313, rs1136754, rs1059563, rs1136903, rs1136749, rs2021171) using the PCR-based KASP assay (Semagn *et al.*, 2014), as were the SNPs tested in the validation study.

SNP selection

SNPs were selected in 17 genes using two strategies. First, SNPs that were previously reported to have associations with HAT or other infectious diseases were selected in *APOLI* (*G1* and *G2* SNPs), *CFH*, *HCAA*, *HPR*, *HP*, *IL1B*, *IL12B*, *IL12RB1*, *IL10*, *IL4R*, *MIF* and *TNFA* (Bucheton *et al.*, 2011; Courtin *et al.*, 2006; Genovese *et al.*, 2010; Hardwick *et al.*, 2013; Ilboudo *et al.*, 2012; Ilboudo *et al.*, 2014; Jamonneau *et al.*, 2012; Kato *et al.*, 2015; MacLean *et al.*, 2004; Sternberg *et al.*, 2005; Stijlemans *et al.*, 2014).

Second, genome sequence data from 230 residents of HAT endemic regions in DRC, Guinea Conakry, Ivory Coast and Uganda (TrypanoGEN consortium, sequences at European Nucleotide Archive Study: EGAS00001002602) and 1000 Genomes Project data (1000 Genomes Project Consortium *et al.*, 2012) from African populations were used to identify sets of unlinked SNP ($r^2 < 0.5$) across *IL6*, *IL4*, *IL8*, *IFNG*, and *HLA-G* (Courtin *et al.*, 2007; Courtin *et al.*, 2013; Ilboudo *et al.*, 2014; Lejon *et al.*, 2002; Sternberg *et al.*, 2005) (MacLean *et al.*, 2004) using the '--indep-pairwise 50 5 0.5' command in plink Plink v1.9 to select SNP with $r^2 < 0.5$ from sliding windows of 50 SNP moving 5 SNP at a time (Chang *et al.*, 2015). A complete list of dbSNP identifiers of SNPs selected is shown in Table S1, see *Extended data* (Fataki Asina, 2020).

Data and statistical analysis

The results were analyzed using Plink V1.9 software (Chang *et al.*, 2015; Purcell *et al.*, 2007) and R (R Core Team, 2008) for viewing. Markers with >40% missing data (--geno 0.4) were removed and individuals with >30% (--mind 0.3) missing data were removed.

Power calculations were undertaken using the genetics analysis package (GAP) in R (R Core Team, 2008; Zhao, 2007).

Fisher's exact test was used to identify associations between phenotypes and SNP loci.

The Bonferroni correction was used to correct for multiple testing. A p value below 0.05/n was considered statistically significant, where n is the number of SNPs in a given comparison after quality control.

Results

Quality control of data

In the candidate gene study, 233 DNA samples were genotyped: 100 active HAT cases, 33 from subjects with latent infections and 100 negative controls with a male/female sex ratio of 0.63. Data were filtered to remove loci and individuals with excessive missing data. After examining the distribution of the data, markers with >40% missing data were removed and individuals with >30% missing data were removed. These filters removed nine SNP loci, one case, four controls and four seropositives. All remaining polymorphisms were in Hardy-Weinberg equilibrium.

For the validation study, 594 DNA samples were genotyped: 164 active HAT cases and 430 negative controls with a male/female sex ratio of 0.58. There was no significant difference in sex ratio between cases and controls ($p=0.56$) or between discovery and validation groups ($p=0.43$).

Association analysis in candidate gene study

Data for the three possible comparisons between the three phenotypes (cases versus controls; latent infections versus controls; and cases versus latent infections) were analysed separately.

Cases and controls. Two SNPs in *IL4* (rs2243258 and rs2243279) and two in *IFNG* (rs2430561, rs2069718) had minor alleles that appeared to be protective against HAT in the comparison between cases and controls (odds ratios <1) before Bonferroni correction (Table 1). After Bonferroni correction, neither remained significant ($p>0.05$).

There was no statistically significant difference in allele frequency for *CFH*, *HP*, *HPR*, *IL1B*, *IL12B*, *IL12RB1*, *IL6*, *IL8*, *IL10*, *TNFA*, *HLAG*, *HCAA*, *MIF*, and *APOL1* polymorphisms.

Latent infections and controls. The minor alleles of *IFNG* (rs2430561 and rs2069718) SNPs were also protective in the comparison between latent infections and controls. The minor (T) allele of *IL6* (rs2069830) was not found at all in the 29 subjects with latent infections but was found at 7% frequency in the controls (Table 2), suggesting that it might be protective against seroconversion.

Table 1. Analysis of association between human African trypanosomiasis patients and negative control subjects.

SNP	Gene	CHR	BP	A1	Case	Control	A2	P	OR	SE	P (HWE)
rs2243258	<i>IL4</i>	5	132012110	T	0.04	0.12	C	0.003	0.31	0.42	0.16
rs2243279	<i>IL4</i>	5	132016227	A	0.04	0.12	G	0.008	0.34	0.43	0.34
rs2430561	<i>IFNG</i>	12	68552522	A	0.09	0.20	T	0.003	0.42	0.30	1.00
rs2069718	<i>IFNG</i>	12	68550162	G	0.31	0.43	A	0.014	0.59	0.21	0.73

CHR, chromosome number; SNP, dbSNP ID; BP, physical position (base-pair in GRCh37); A1, minor allele name; Case, frequency of this allele in cases; Control, frequency of this allele in controls; A2, major allele name; P, exact p-value; OR, estimated odds ratio (for A1); SE, standard error of odds ratio; P (HWE): Hardy-Weinberg equilibrium p value for unaffected individuals.

Table 2. Association analysis between asymptomatic latent human Africa trypanosomiasis infection subjects and negative controls.

SNP	Gene	CHR	BP	A1	Latent	Control	A2	P	OR	SE	P (HWE)
rs2069718	<i>IFNG</i>	12	68550162	G	0.24	0.43	A	0.011	0.41	0.360	1.00
rs2069728	<i>IFNG</i>	12	68547784	T	0.44	0.27	C	0.020	2.08	0.320	1.00
rs2069830	<i>IL6</i>	7	22767137	T	0.00	0.07	C	0.032	0.00	inf	0.05
rs71889624	<i>IL4</i>	5	132013430	DEL	0.00	0.06	CTGA	0.048	0.00	inf	0.03
rs35235644	<i>MIF</i>	22	24237822	C	0.02	0.10	G	0.062	0.18	1.039	0.58

CHR, chromosome number; SNP, dbSNP ID; BP, physical position (base-pair in GRCh37); A1, minor allele name; Latent, frequency of this allele in latent infections; Control, frequency of this allele in controls; A2, major allele name; P, exact p-value; OR, estimated odds ratio (for A1); SE, standard error of odds ratio; P (HWE): Hardy-Weinberg equilibrium p value for unaffected individuals; inf, infinity; DEL, deletion.

Cases and latent infections. Three SNPs in *IL4* (rs2243258, rs2243279 and rs71889624) were associated with protection against progression from latent infection to case (Table 3). Two of these were also just as strongly associated with cases and controls, despite less than a third of the number of samples of latent infections being available. This was a consequence of a higher frequency of the minor allele in latent infections than in controls. Carriers of the T allele of rs2243258 and those of the A allele of rs2243279 of *IL4* have a reduced risk of developing illness; as do carriers of the T allele of rs2069728 of *IFNG*, for asymptomatic carriers in relation to the controls.

The complete absence of the T allele of rs2069830 of *IL6* in latent infections also suggests that this SNP is associated

with risk of progression to active HAT. None of the associations with the latent infections remained significant after Bonferroni correction.

Validation study. *IL4* and *IFNG* SNPs that were marginally significant in the candidate gene study were not significant in the validation study (Table 4).

Discussion

In the candidate gene study, 87 SNPs in 17 candidate genes remained after quality control. We found suggestive associations with HAT at SNP loci in *IL4*, *IFNG*, *IL6* and *MIF*, but none of these remained significant after a Bonferroni correction. It was particularly notable that no association was found

Table 3. Association analysis between latent infections and cases.

SNP	Gene	CHR	BP	A1	Case	Latent	A2	P	OR	SE	P (HWE)
rs2243279	<i>IL4</i>	5	132016227	A	0.04	0.16	G	0.003	0.21	0.52	0.25
rs2243258	<i>IL4</i>	5	132012110	T	0.04	0.16	C	0.003	0.22	0.52	0.27
rs2069830	<i>IL6</i>	7	22767137	T	0.12	0.00	C	0.004	NA	NA	0.33
rs2069728	<i>IFNG</i>	12	68547784	T	0.26	0.44	C	0.019	0.45	0.32	1.00
rs71889624	<i>IL4</i>	5	132013430	DEL	0.07	0.00	CTGA	0.030	NA	NA	1.00
rs35235644	<i>MIF</i>	22	24237822	C	0.11	0.02	G	0.044	6.36	1.03	1.00

CHR, chromosome; SNP: dbSNP ID; BP, physical position (base-pair in GRCh37); A1, minor allele; Case, frequency of minor allele in cases; Latent, frequency of this allele in latent infections; A2, major allele; P, exact p-value; OR, estimated odds ratio (for A1); SE, standard error of odds ratio; P (HWE), Hardy Weinberg equilibrium p value for unaffected individuals; DEL, deletion.

Table 4. Validation study.

Source	CHR	SNP	Gene (allele)	BP	A1	A2	P	OR	SE	P (HWE)	Cases	Controls
Candidate gene	7	rs1818879	<i>IL6</i>	22772727	A	G	0.810	1.07	0.31	0.52	99	
Validation study	7	rs1818879	<i>IL6</i>	22772727	A	G	0.640	0.89	0.21	0.23	164	430
Candidate gene	5	rs2243258	<i>IL4</i>	132012110	T	C	0.003	0.30	0.42	0.12	99	
Validation study	5	rs2243258	<i>IL4</i>	132012010	T	C	0.330	0.79	0.23	0.40	164	430
Candidate gene	12	rs2430561	<i>IFNG</i>	68552522	A	T	0.003	0.41	0.30	0.59	99	
Validation study	12	rs2430561	<i>IFNG</i>	68552422	A	T	0.810	0.94	0.18	0.70	164	430
Validation study	22	rs71785313	<i>APOL1</i> (G2)	36662046	2	1	0.010	0.55	0.24	0.63	164	430
Candidate gene	22	rs71785313	<i>APOL1</i> (G2)	36662046	T	A	0.480	0.75	0.40	0.45	99	96
Candidate gene	22	rs73885319	<i>APOL1</i> (G1)	36661906	G	A	0.330	1.27	0.26	1.00	99	96
Validation study	22	rs73885319	<i>APOL1</i> (G1)	36661806	G	A	0.330	0.82	0.19	0.71	164	430

CHR, chromosome; SNP, dbSNP ID; Gene (allele), gene and also allele for *APOL1*; BP, physical position (base-pair in GRCh37); A1, minor allele; A2, major allele; P, exact p-value; OR, estimated odds ratio (for A1); SE, standard error of odds ratio; P (HWE), Hardy Weinberg equilibrium p value for unaffected individuals.

with *APOL1* despite the *APOL1* protein being lytic to *T. brucei* and some alleles being lytic to *T. b. rhodesiense* and *T. b. gambiense* in vitro (Genovese *et al.*, 2010). Associations have been found with the *APOL1 G1* allele in comparisons with latent infections in Guinea (Cooper *et al.*, 2017). In that study, latent infections had been followed for two years, during which time they remained serologically positive but parasitologically negative. In our study, latent infections were defined as serologically positive but parasitologically negative at a single visit. This different case definition and the small sample size of latent infections ($n=33$) may account for the difference in outcomes. Associations have also been found with *APOL1 G2* frequencies between cases and controls in *T. b. rhodesiense* infections in Uganda and Malawi (Cooper *et al.*, 2017; Kamoto *et al.*, 2019), but another study in Uganda found no association with *APOL1 G2*. Although there is strong evidence for a role for *APOL1* in HAT, the role of the different alleles in disease response is much less clear and may depend on the immunological context.

IL4

The minor alleles of rs2243258 and 2243279 were suggestively associated with protection against development of HAT in the case-control comparison and with protection against progression from latent infection to HAT, with odds ratios of 0.28 ± 0.06 in cases versus controls, indicating a potentially large effect on the outcome of infection. However, rs2243258 showed no sign of association with HAT in the validation study (Table 4).

A similar study in the same Bandundu focus published in 2007 tested four SNPs in *IL4* and found no association with disease, but none of those SNPs were the ones with suggestive p values in the present study (Courtin *et al.*, 2007). Another TrypanoGEN study in Ivory Coast using the same SNP set as in the present study found five *IL4* SNPs suggestively associated with risk of developing a latent infection (uncorrected p values <0.05) (Ahouty *et al.*, 2017). None of those five loci were associated with disease in our study. If these are genuine associations, two different haplotypes with different modes of action may be regulating responses to infection in the two countries.

IL4 is an anti-inflammatory cytokine that is more highly expressed in late stage or chronic infections in mice and may be involved in preventing an excessive inflammatory response, causing tissue damage (Bakhiet *et al.*, 1996; Namangala *et al.*, 2009). However, the only study of *IL4* in humans with HAT, which we are aware of, found no differences in *IL4* levels in the cerebrospinal fluid of *T. rhodesiense*-HAT patients (Maclean *et al.*, 2001).

IL6

IL6 (rs2069830, T allele) was suggestively associated with protection against HAT. This result adds to the evidence from previous studies for a role for *IL6* in protection against *Tbg* HAT (Bucheton *et al.*, 2011; Sternberg *et al.*, 2005).

A previous study in the same province of Bandundu found a significant association at *IL6*rs2069849 (Courtin *et al.*, 2007). This SNP was not included in the present study, but this finding

supports a role for *IL6* variants in the development of HAT. A recent study in Guinea found that *IL6*rs1818879 was associated with a lower risk of progressing from latent infection to active disease (Kabore *et al.*, 2017) and an Ivorian study found that rs62449495 and rs2069830 have a protective effect against developing active *Tbg* HAT (Ahouty *et al.*, 2017). The minor allele of this last SNP (rs2069830) was also found in the same study to be protective against progressing from latent infection to cases (Ahouty *et al.*, 2017).

IL6 is an inflammatory protein that plays an important role in host immunity, particularly during the acute phase of the infection. Its production increases considerably in the late phase of infection and decreases dramatically after treatment, suggesting that it plays an important role in humans infected with *Tbg* (Lejon *et al.*, 2002).

IFNG

The minor alleles of rs2069718, rs2430561 and rs2069728 were associated with protection against progression in *Tbg* HAT in the case versus control, latent infection versus control and latent infection versus case comparisons, respectively, although the results were not significant after Bonferroni correction. Individuals with the T allele of rs2069728 had about half the risk of developing HAT in the latent infection versus case comparison, as compared to carriers of the C allele. Two of the three SNPs within the same gene were tested in an Ivorian population and there was no protective effect in a comparison of cases versus controls ($p>0.05$) (Ahouty *et al.*, 2017). A previous study of cases and controls in the same focus in Bandundu (Courtin *et al.*, 2007) revealed no association with HAT at four *IFNG* SNPs but did not include those that were suggestively associated in this study. SNP rs2430561 was included in the validation study and no evidence of any association was found (Table 4). A parallel study in Guinea with the same SNP (rs2430561) as the present study also found that *IFNG* was not associated with HAT in both case versus latent infection and latent infection versus control comparisons (Kabore *et al.*, 2017). Recent studies on humans suggest that *IFNG* can be associated with neurological symptoms in *Tbr* HAT (Kato *et al.*, 2016) but it is not known if this is also true of *Tbg* HAT. *IFNG* is involved in parasite control in mice (Hertz *et al.*, 1998) and recently, its production was found to be elevated above background in the plasma of individuals with latent infections after stimulation with *Tbg* lysates but not in controls or cases of active HAT (Ilboudo *et al.*, 2016).

Latent infections

It is important to note that more suggestive associations were observed in comparisons of latent infections with cases or controls than were observed in the case versus control comparison, despite the small number of latent infection samples available (only 29 after quality control). This may be the most important observation of this study and suggests that latent infections are a genetically distinct group, as has been found in Guinea and Ivory Coast (Ilboudo *et al.*, 2016; Kabore *et al.*, 2017). Latent infections might be an important reservoir of infection, but their role and significance in the epidemiology of HAT is

poorly understood. If people with latent infections have distinct genetic characteristics, it may be possible to develop genetic approaches to estimating the size of this group.

Validation study

Despite more samples being available in the validation study, including 164 cases and 430 controls, *IL4* and *IFNG* SNPs were not significantly associated with HAT. Random sample variation may account for the difference in outcome of the candidate gene and validation studies that used two different sets of samples. The negative result of the validation study shows how important it is to validate observations from candidate gene studies using fresh datasets.

Conclusions

In conclusion, our survey reveals that two SNPs in each of *IL4* (rs2243258, T allele, and rs2243279, A allele) and *IFNG* (rs2430561, A allele, and rs2069718, G allele) appeared to be associated with a low risk of developing symptomatic *Tbg* infection in the Congolese population; however, these associations were not significant after Bonferroni correction or validation. The genetic factors of susceptibility to infection by *Tbg* in DRC were not replicated in other populations, suggesting that genetic risk factors may vary according to the population.

Data availability

Underlying data

Raw genotyping data on European Genome-phenome Archive, Accession number EGAS00001004365: <https://identifiers.org/ega.study:EGAS00001004365>.

Access to the data will be granted to life science researchers for research purposes only. Users should write to Prof. Dieudonné Mumba Ngoyi (mumbadieudonne@yahoo.fr) who will authorise the EGA to release the data to the named researchers after completion of a data access agreement.

Harvard Dataverse: SNPs in *IL4* and *IFNG* show no protective associations with human African trypanosomiasis in the Democratic Republic of the Congo: a case-control study. <https://doi.org/10.7910/DVN/I7ODO6> (Fataki Asina, 2020).

This project contains the following underlying data:

- DRC_CAS_CON_Candidate_Validation.xls (complete Plink output for the four SNP for used in the validation study)
- DRC_Revised_Candidate_Gene_Analysis-1.xlsx (Complete Plink output for all SNP for the four contrasts: 1) Cases v Controls 2) Latent (SERO) v Cases 3) Latent (SERO) v Controls 4) Latent (SERO) and Cases v Controls)

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

Extended data

Harvard Dataverse: SNPs in *IL4* and *IFNG* show no protective associations with human African trypanosomiasis in the Democratic Republic of the Congo: a case-control study. <https://doi.org/10.7910/DVN/I7ODO6> (Fataki Asina, 2020).

This project contains the following extended data:

- SupplementaryDataTable_S1.txt (Table S1, SNPs genotyped in this study including rs id and co-ordinates in GRCh37 genome build)

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

Acknowledgments

[H3Africa consortium](#). National Institute of Biomedicale Research (INRB), DRC. National Program of control of HAT (PNLTHA), DRC. We thank the population of Masi-Manimba DRC for participating in this study.

We are grateful to the members of TrypanoGEN group: Julius Mulindwa, Magambo Phillip Kimuda, Mathurin Koffi, Justin Windingoudi Kaboré, Bernadin Ahouty, Gustave Simo, Elvis Ofon, John Enyaru, John Chisi, Kelita Kamoto, Martin Simuunza, Vincent P. Alibu, Veerle Lejon, Vincent Jamonneau, Mamadou Camara, Bruno Bucheton, Christiane Hertz-Fowler, Issa Sidibe, Enock Matovu.

References

- Ahouty B, Koffi M, Ilboudo H, *et al.*: **Candidate genes-based investigation of susceptibility to Human African Trypanosomiasis in Côte d'Ivoire.** *PLoS Negl Trop Dis.* 2017; 11(10): e0005992.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bakhiet M, Jansson L, Büscher P, *et al.*: **Control of parasitemia and survival during *Trypanosoma brucei brucei* infection is related to strain-dependent ability to produce IL-4.** *J Immunol.* 1996; 157(8): 3518–3526.
[PubMed Abstract](#)
- Bucheton B, Macleod A, Jamonneau V: **Human host determinants influencing the outcome of *Trypanosoma brucei gambiense* infections.** *Parasite Immunol.* 2011; 33(8): 438–447.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Büscher P, Cecchi G, Jamonneau V, *et al.*: **Human African trypanosomiasis.**

Lancet. 2017; 390(10110): 2397–2409.

[PubMed Abstract](#) | [Publisher Full Text](#)

Chang CC, Chow CC, Tellier LC, *et al.*: **Second-generation PLINK: rising to the challenge of larger and richer datasets.** *Gigascience.* 2015; 4: 7.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Cooper A, Ilboudo H, Alibu VP, *et al.*: **APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis.** *eLife.* 2017; 6: e25461.

[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Courtin D, Argiro L, Jamonneau V, *et al.*: **Interest of tumor necrosis factor- α -308 G/A and interleukin-10 -592 C/A polymorphisms in human African trypanosomiasis.** *Infect Genet Evol.* 2006; 6(2): 123–129.

[PubMed Abstract](#) | [Publisher Full Text](#)

- Courtin D, Milet J, Jamonneau V, *et al.*: Association between human African trypanosomiasis and the IL6 gene in a Congolese population. *Infect Genet Evol.* 2007; 7(1): 60–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Courtin D, Milet J, Sabbagh A, *et al.*: HLA-G 3' UTR-2 haplotype is associated with Human African trypanosomiasis susceptibility. *Infect Genet Evol.* 2013; 17: 1–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fataki Asina O: SupplementaryDataTable_S1.txt", SNPs in IL4 and IFNG show no protective associations with human African trypanosomiasis in the Democratic Republic of the Congo: a case-control study. *Harvard Dataverse*, V1. 2020.
<http://www.doi.org/10.7910/DVN/I7ODO6/3QFWX>
- Gabriel S, Ziaugra L, Tabbaa D: SNP Genotyping Using the Sequenom MassARRAY iPLEX Platform. *Curr Protoc Hum Genet.* 2009; Chapter 2: Unit 2.12.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Genovese G, Friedman DJ, Ross MD, *et al.*: Association of Trypanolytic ApoL1 Variants with Kidney Disease in African-Americans. *Science.* 2010; 329(5993): 841–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hardwick RJ, Ménard A, Sironi M, *et al.*: Haptoglobin (HP) and Haptoglobin-related protein (HPR) copy number variation, natural selection, and trypanosomiasis. *Hum Genet.* 2013; 133(1): 69–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Headrick DR: Sleeping sickness epidemics and colonial responses in East and Central Africa, 1900–1940. *PLoS Negl Trop Dis.* 2014; 8(4): e2772.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hertz CJ, Filutowicz H, Mansfield JM: Resistance to the African trypanosomes is IFN-gamma dependent. *J Immunol.* 1998; 161(12): 6775–6783.
[PubMed Abstract](#)
- Ilboudo H, Berthier D, Camara M, *et al.*: APOL1 expression is induced by *Trypanosoma brucei gambiense* infection but is not associated with differential susceptibility to sleeping sickness. *Infect Genet Evol.* 2012; 12(7): 1519–1523.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ilboudo H, Bras-Gonçalves R, Camara M, *et al.*: Unravelling Human Trypanotolerance: IL8 is Associated with Infection Control whereas IL10 and TNF α Are Associated with Subsequent Disease Development. *PLoS Pathog.* 2014; 10(11): e1004469.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ilboudo H, Jamonneau V, Koffi M, *et al.*: Trypanosome-induced Interferon- γ production in whole blood stimulation assays is associated with latent *Trypanosoma brucei gambiense* infections. *Microbes Infect.* 2016; 18(6): 436–440.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jamonneau V, Ilboudo H, Kaboré J, *et al.*: Untreated human infections by *Trypanosoma brucei gambiense* are not 100% fatal. *PLoS Negl Trop Dis.* 2012; 6(6): e1691.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kabore JW, Ilboudo H, Noyes H, *et al.*: Candidate gene polymorphisms study between human African trypanosomiasis clinical phenotypes in Guinea. *PLoS Negl Trop Dis.* 2017; 11(8): e0005833.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kande Betu Kumesu V: Annual Report 2011. National Program for the Control of Trypanosomiasis PNLTHA. DR Congo. 2012.
- Kato CD, Alibu VP, Nanteza A, *et al.*: Interleukin (IL)-6 and IL-10 Are Up Regulated in Late Stage *Trypanosoma brucei rhodesiense* Sleeping Sickness. *PLoS Negl Trop Dis.* 2015; 9(6): e0003835.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kato CD, Matovu E, Mugasa CM, *et al.*: The role of cytokines in the pathogenesis and staging of *Trypanosoma brucei rhodesiense* sleeping sickness. *Allergy Asthma Clin Immunol.* 2016; 12: 4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kamoto K, Noyes H, Nambala P, *et al.*: Association of APOL1 renal disease risk alleles with *Trypanosoma brucei rhodesiense* infection outcomes in the northern part of Malawi. *PLoS Negl Trop Dis.* 2019; 13(8): e0007603.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kennedy PG: Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). *Lancet Neurol.* 2013; 12(2): 186–194.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kimuda MP, Noyes H, Mulindwa J, *et al.*: No evidence for association between APOL1 kidney disease risk alleles and Human African Trypanosomiasis in two Ugandan populations. *PLoS NTD.* 2018; 12(2): e0006300.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lejon V, Lardon J, Kenis G, *et al.*: Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of *Trypanosoma brucei gambiense* sleeping sickness patients before and after treatment. *Trans R Soc Trop Med Hyg.* 2002; 96(3): 329–333.
[PubMed Abstract](#) | [Publisher Full Text](#)
- MacLean L, Chisi JE, Odiit M, *et al.*: Severity of Human African Trypanosomiasis in East Africa Is Associated with Geographic Location, Parasite Genotype, and Host Inflammatory Cytokine Response Profile. *Infect Immun.* 2004; 72(12): 7040–7044.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Maclean L, Odiit M, Sternberg JM: Nitric Oxide and Cytokine Synthesis in Human African Trypanosomiasis. *J Infect Dis.* 2001; 184(8): 1086–1090.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Namangala B, De Baetselier P, Beschin A: Both Type-I and Type-II Responses Contribute to Murine Trypanotolerance. *J Vet Med Sci.* 2009; 71(3): 313–318.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ofon E, Noyes H, Mulindwa J, *et al.*: A polymorphism in the haptoglobin, haptoglobin related protein locus is associated with risk of human sleeping sickness within Cameroonian populations. *PLoS Negl Trop Dis.* 2017; 11(10): e0005979.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Purcell S, Neale B, Todd-Brown K, *et al.*: PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *Am J Hum Genet.* 2007; 81(3): 559–575.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- R Core Team: R: A language and environment for statistical computing. Vienna, Austria 2008.
[Reference Source](#)
- Report of a WHO Expert Committee: Control and surveillance of human African trypanosomiasis (No. 984) 2013.
[Reference Source](#)
- Semagn K, Babu R, Hearne S, *et al.*: Single nucleotide polymorphism genotyping using Kompetitive Allele Specific PCR (KASP): overview of the technology and its application in crop improvement. *Mol Breeding.* 2014; 33: 1–14.
[Publisher Full Text](#)
- Sternberg JM, Rodgers J, Bradley B, *et al.*: Meningoencephalitic African trypanosomiasis: Brain IL-10 and IL-6 are associated with protection from neuro-inflammatory pathology. *J Neuroimmunol.* 2005; 167(1–2): 81–89.
[Publisher Full Text](#) | [Free Full Text](#)
- Stijlemans B, Leng L, Brys L, *et al.*: MIF Contributes to *Trypanosoma brucei* Associated Immunopathogenicity Development. *PLoS Pathog.* 2014; 10(9): e1004414.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- 1000 Genomes Project Consortium, Goncalo GA, Adam A: An integrated map of genetic variation from 1,092 human genomes. *Nature.* 2012; 491(7422): 56–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Van Meirvenne N, Magnus E, Büscher P: Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with *Trypanosoma brucei gambiense*. *Acta Tropica.* 1995; 60(3): 189–199.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Zhao J: gap: Genetic Analysis Package. *J Stat Softw.* 2007; 23(8).
[Reference Source](#)

Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 09 September 2020

<https://doi.org/10.21956/aasopenres.14084.r27777>

© 2020 Kato C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Charles D. Kato 

School of Bio-security, Biotechnical & Laboratory Sciences, College of Veterinary Medicine, Animal Resources & Bio-security, Makerere University, Kampala, Uganda

Human African trypanosomiasis especially gHAT has been shown to present with a varying clinical outcome and disease course. Unlike rHAT that is acute and fatal, gHAT has been characterized with spontaneous cure among patients refusing treatment. The factors responsible for this varied response and outcome are still interesting areas for research. In this manuscript, the authors look at host genetic variation as one of the key factors. The authors have investigated polymorphisms within 17 candidate genes (*APOL1* [*G1* and *G2*], *CFH*, *HLA-A*, *HPR*, *HP*, *IL1B*, *IL12B*, *IL12RB1*, *IL10*, *IL4R*, *MIF*, *TNFA*, *IL6*, *IL4*, *IL8*, *IFNG*, and *HLA-G*). This research is of interest and will contribute towards our understanding of gHAT clinical spectrum and thus guide the design of sustainable control approaches. However, a number of improvements as highlighted below are required so as to make the work more interesting and conclusive.

- Throughout the write out, including the conclusion, the authors should clearly indicate that the results are for gHAT since these findings might not directly apply to rHAT that was not considered in this manuscript.
- I would have liked to see improvements in the background section. The study concludes as “no evidence of an association of HAT with *IL4* and *IFNG* SNPs or with *APOL1* *G1* and *G2* alleles, which have been found to be protective in other studies”. However, the introduction elaborates more about other markers and does not give evidence of studies that have reported protective effects of *IL4* and *IFNG*.
- Within the Introduction section, the authors need to provide references for this statement “It is now recognized that some individuals self-cure after developing a latent infection”.
- “For the validation study, 594 DNA samples were genotyped”. Validation of a marker is a critical step in association studies. However, the connection between the discovery and validation steps are not well articulated. The authors say they validated with 594 samples but it is not clear about which population and sampling period that these samples were

collected. Were these samples collected from the same locality and matched accordingly? My other concern is why the validation step did not include latent infection. If this was an issue of getting samples then it should be indicated.

- The last sentence in the result section of the abstract “A validation study using more samples was run to determine if the absence of significant association was due to lack of power” is hanging and appears incomplete.
- About the genetic analysis I would have liked to see the different polymorphisms within the analysed gene and how these loci are linked.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Molecular biology, Immunology and Microbiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 18 August 2020

<https://doi.org/10.21956/aasopenres.14084.r27697>

© 2020 Chimusa E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Emile Chimusa 

Department of Pathology, Division of Human Genetics, University of Cape Town, Cape Town, South Africa

The manuscript by Fataki *et al.* presents a study that examines genetic variation in different outcomes of Infection with trypanosomes. They leverage a case-control design study, a total of 233 samples were recruited in the district of Masi-Manimba, in the province of Kwilu from Democratic Republic of the Congo, and were genotyped of which 100 active HAT cases, 33 from subjects with latent infections and 100 negative controls. The study by Fataki *et al.* is relevant in the field, it is clear, well written and timely, particularly the DRC data is important. However, I have major concerns on the statistics/data analysis.

1. It is not clear how the validation analysis was conducted using the additional 594 individuals, including 164 cases and 430 controls. The authors need to elaborate and make it more clear.
2. The study presented by Fataki *et al.* suffers from lower sample size, it could be much better to increase power by performing meta-analysis of DRC against the additional 594 individuals, including 164 cases and 430 controls.
3. The study by Fataki *et al.* can benefit from performing the distribution of minor allele frequency among case-control DRC and compare with the additional 594 individuals, including 164 cases and 430 controls and also 1000 Genomes Project data and importantly discussion on population specific minor allele frequency at these genotyped polymorphisms.
4. It could be much better to provide heatmap Linkage disequilibrium (LD) at the genotyped gene regions and discuss patterns of LD among these sample settings.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Bioinformatics and Computational Biology, Population genetics and Genome-Wide Association Studies

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
